Author: admin

Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases. This agreement expands Chiesi’s comprehensive R&D program in bronchiectasis, a respiratory disease with high unmet medi

NEW YORK, Nov. 19, 2023 /PRNewswire/ — The influenza diagnostics market is estimated to grow at a CAGR of 6.95% from 2022 to 2027. The market size is forecast to increase by USD 466.18 million, according to Technavio. The rising adoption of rapid diagnostic products in physician office labora

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: